Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2018
Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?Liang Zeng, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to CrizotinibWenjuan Jiang, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung AdenocarcinomaLiang Zeng, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung AdenocarcinomaLiang Zeng, Yongchang Zhang, Nong Yang
The Lancet. Oncology|December 4, 2018
Lung squamous carcinoma involving the lip and cheekBinjie Yan, Fang Wu, Nong Yang, et al.
Thoracic Cancer|February 22, 2019
Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patientYijuan Hu, Lili Xiao, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2020
Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFRXiangyu Zhang, Wenjuan Jiang, Nong Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2019
Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation SequencingChunhua Zhou, Liang Zeng, Yongchang Zhang, et al.
JTO Clinical and Research Reports|September 30, 2021
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of ChemotherapyYuling Zhou, Liang Zeng, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2020
Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus PyrotinibYuling Zhou, Wenjuan Jiang, Nong Yang, et al.
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2018
Should Crizotinib Take It All in ROS1-Positive Non-Small-Cell Lung Cancer?Liang Zeng, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to CrizotinibWenjuan Jiang, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 25, 2018
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung AdenocarcinomaLiang Zeng, Nong Yang, Yongchang Zhang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung AdenocarcinomaLiang Zeng, Yongchang Zhang, Nong Yang
The Lancet. Oncology|December 4, 2018
Lung squamous carcinoma involving the lip and cheekBinjie Yan, Fang Wu, Nong Yang, et al.
Thoracic Cancer|February 22, 2019
Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patientYijuan Hu, Lili Xiao, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|July 15, 2020
Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFRXiangyu Zhang, Wenjuan Jiang, Nong Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2019
Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation SequencingChunhua Zhou, Liang Zeng, Yongchang Zhang, et al.
JTO Clinical and Research Reports|September 30, 2021
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of ChemotherapyYuling Zhou, Liang Zeng, Nong Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2020
Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus PyrotinibYuling Zhou, Wenjuan Jiang, Nong Yang, et al.
Pageof 21